| Date | Title | Description |
| 26.06.2026 | CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union | Recommendation follows an Article 20 non-pharmacovigilance procedure
Patients currently on TAVNEOS treatment should consult their treating physician
ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal P... |
| 17.04.2026 | World Hemophilia Day 2026 - April 17, 2026 - "Diagnosis: First step to care." | MONTREAL, April 17, 2026 /PRNewswire/ -- On April 17, 2026, the global inherited bleeding disorders community will come together on World Hemophilia Day to advocate for all inherited bleeding disorders. This year's theme of "Diagnosis:... |
| 27.10.2025 | CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) | Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL's base fractiona... |
| 06.08.2025 | Raising a Child with Hemophilia: Sixth Edition Now Available! | "Raising a Child with Hemophilia" Sixth Edition
Parenting a child with hemophilia is difficult in any circumstance, but less so with access to a comprehensive guide that carefully walks parents through each stage of their child's ... |
| 27.06.2025 | DataBahn.ai Secures $17 Million to Revolutionize Data Management with AI | In the bustling tech landscape of Dallas, DataBahn.ai has emerged as a beacon of innovation. The company recently announced a significant milestone: raising $17 million in Series A funding. This infusion of capital, led by Forgepoint Capita... |
| 27.06.2025 | DataBahn.ai: $17 Million Series A Raised For Transforming Enterprise Data Pipelines | DataBahn.ai, the creator of a security-native data pipeline platform built for modern enterprise workloads, announced it has raised $17 million in Series A funding. The funding round was led by Forgepoint Capital, with participation from S3... |
| 11.06.2025 | The Rising Tide of NBA Sponsorships: A Game-Changer for Teams and Brands | The NBA is on a roll. Sponsorship revenue surged to $1.62 billion this season, marking an 8% increase from last year. This growth is not just a number; it’s a sign of changing tides in sports marketing. The league is evolving, and brands ar... |
| 10.06.2025 | Urban League of Greater Philadelphia Announces Name Change, Regional Expansion and $150K in Student Scholarships at Signature Gala | Urban League of Greater Philadelphia
The Urban League of Greater Philadelphia (ULGP) formally announces new name and territory expansion, now serving 4.4 million residents (up from 1.6 Million). This was announced at it's sold out Gala with... |
| 25.04.2025 | A Lifeline for Hemophilia: Sanofi and Sobi's Renewed Commitment to Global Health | In a world where access to healthcare can be as elusive as a mirage, the partnership between Sanofi, Sobi, and the World Federation of Hemophilia (WFH) stands as a beacon of hope. On April 25, 2025, these organizations announced a significa... |
| 25.04.2025 | Sobi and Sanofi’s Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program | Sobi and Sanofi’s Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program
Fri, Apr 25, 2025 06:00 CET Report this content
Up to five-year contract extension to support the WFH Humanitarian Aid Progra... |
| 25.04.2025 | Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program | Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance
MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with San... |
| 17.04.2025 | World Hemophilia Day 2025 - April 17, 2025 - "Access for all: Women and girls bleed too" | MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women an... |
| 19.11.2024 | The Rise of Biotech: ORIC Pharmaceuticals and OmniScience Lead the Charge | In the ever-evolving landscape of biotechnology, two companies are making waves: ORIC Pharmaceuticals and OmniScience. Both are harnessing innovation to tackle pressing health challenges. Their approaches, while distinct, share a common goa... |
| 14.11.2024 | Vivo, OmniScience's genAI-powered clinical trial control tower, wins 2024 The Whale Tank competition at Innovation Network Gathering | OmniScience
Angela Holmes, CEO of OmniScience, speaks at The Whale Tank, presented at the 2024 Innovation Network Gathering, on how her company is using AI to keep pace with the clinical trial data explosion
OmniScience, a disrupter in the ... |
| 12.09.2024 | The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and Action | X-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li... |
| 09.09.2024 | More space for healthtech start-ups on the Novartis Campus |
Digitalisation is one of the megatrends in the healthcare sector. It not only promises greater efficiency, but also new possibilities in diagnostics and therapeutics. As this field requires expertise that traditional healthcare companies o... |
| 09.07.2024 | CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season | CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States.
Centers for Disease Control and Prevention (CDC) trend findings indicate a significant ... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 17.04.2024 | World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders" | MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is "Equitable access for all: recognizing all bl... |
| 04.03.2024 | Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results | –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)–
–Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline effic... |
| 12.10.2023 | CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites | MELBOURNE, Australia, Oct. 12, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was ... |
| 26.02.2023 | CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing | Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year Garadacimab... |
| 13.12.2022 | CSL Announces Next CEO & Managing Director | Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023
MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has a... |
| 10.12.2022 | CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatm... | Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results reinforced safety of treatment, with no seriou... |
| 05.12.2022 | The most expensive drug in the world has a $3.5 million price tag. 2 potential patients share their hopes and fears for the one-time treatment. | Bryen Lackey, 18, has the genetic bleeding disorder hemophilia B. He said he could be interested in receiving a newly approved gene therapy if his doctors recommended it. James Lackey
The FDA has approved a new gene therapy to treat hemophi... |
| 20.09.2022 | Healthcare Trends: Life Sciences Companies Are Becoming Supply Chain Leaders | Assume our business is always about the patient. That was how Michael Schmidt, co-founder and executive board member of Tenthpin Management Consultants, introduced a panel of clinical supply chain experts who shared their thoughts about whe... |
| 12.09.2022 | Six New Member Companies Join the International Consortium for Innovation and Quality in Pharmaceutical Development | IQ continues to grow as an organization and advance key industry initiatives while delivering innovative approaches and effective therapies to patients. We look forward to mutually beneficial collaboration and progress of our portfolio to e... |
| 24.05.2022 | FDA accepts priority review of CSL-uniQure hemophilia B gene therapy; Fosun Pharma nets another deal | The first potential gene therapy for hemophilia B has gotten one step closer to reaching patients as the FDA has accepted CSL Behring’s BLA for its uniQure-partnered one-time treatment. The therapy, dubbed etranacogene dez... |
| 07.02.2022 | From the Athletic Field to the Research Lab ― How Uplifting Athletes is Supporting the Rare Disease Community | Six of nine rare disease researchers who received Uplifting Athletes grants pictured here with Executive Director Rob Long (left) and GM Brett Brackett (right). "We believe these all-star scientists deserve to be lauded with the same e... |
| 13.01.2022 | Uplifting Athletes Announces Young Investigator Draft Class of 2022 | 2022 Young Investigator Draft We believe these all-star scientists deserve to be lauded with the same excitement afforded to college and professional athletes, many of whom partner closely with us to support our mission,” said Rob Long, Exe... |
| 04.10.2021 | Thermo Fisher expands into Switzerland as part of CSL collaboration | Just days after Thermo Fisher Scientific prepped to expand a St. Louis plant, the company announced it’s taking over a new, 1.5 million-square-foot site in Switzerland with plans to add 200 new employees.
The move is a part o... |
| 31.03.2021 | Uplifting Athletes Presents $140,000 in Rare Disease Research Grants at 2021 Young Investigator Draft | Uplifting Athletes Young Investigator Draft Presented by CSL Behring
PHILADELPHIA (PRWEB) March 31, 2021
Uplifting Athletes, a nonprofit organization serving the Rare Disease Community, awarded $140,000 in medical research grants last night... |
| 19.11.2020 | New Harris Poll Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy | |
| 05.11.2020 | CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients | |
| 15.07.2020 | Two Out of Three Rare Disease Patients in Asia-Pacific Do Not Receive the Best-available Care, According to an Economist Intelligence Unit Survey | Knowledge of rare diseases among healthcare professionals is lacking:
o 34% do not know if there is a definition for rare diseases o 35% do not know if there is a national rare disease policy
14% of healthcare professionals report never enc... |
| 25.06.2020 | CSL Behring, uniQure in $2B deal to in-license hemophilia gene therapy | A Dutch biotech company developing a gene therapy for hemophilia has made a deal with the U.S.-based division of an Australian company that will enabled it to be marketed around the world.
Amsterdam-based uniQure said Wednesday that King of... |
| 03.06.2020 | Forbion leads $62.5M round for neuro startup as ex-Teva R&D chief takes control; CSL Behring inks gene therapy pact in immunology | → Forbion has led a $62.5 million round for Prilenia Therapeutics to fund two late-stage trials in Huntington’s disease and amyotrophic lateral sclerosis. Michael Hayden, the former Teva R&D chief who’s been serving ... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 06.02.2020 | European rare disease biotech Azafaros grabs $28M early funding round | Azafaros has grabbed €25 million ($27.5 million) in a series A investment boost as it looks to push on with its pipeline focused on rare metabolic disorders.
The financing round for the two-year-old biotech was led by Forbion, with extra ca... |
| 13.05.2016 | Here are the winners of the 2016 PACT Enterprise Awards | The Pennsylvania Convention Center hosted a crowd of some 900 investors and stakeholders Thursday to celebrate the winners of the 2016 PACT Enterprise Awards.
Dean Miller, president and CEO of the Philadelphia Alliance for Capital and Techn... |
| 02.06.2015 | The Backyard Effect: Finding The Secret Sauce For Growing An Entrepreneurial Ecosystem | Tom Walker Contributor
Tom Walker is president and CEO of Rev1 Ventures
More posts by this contributor
The Backyard Effect: Finding The Secret Sauce For Growing An Entrepreneurial Ecosystem
Experts could debate all day long the ingredients ... |
| 19.02.2015 | Novartis leads a $28M round for rare disease biotech Merganser | Pennsylvania's Merganser Biotech raised a $28 million A round with the help of Novartis ($NVS) Venture Fund, paying the company's way as it homes in on iron-related diseases.
The company is at work on peptides that mimic hepcidin, a hormone... |
| 21.01.2013 | Therapeutic could improve hemophilia B patients’ quality of life with reduced jabs | Last year, it secured orphan drug status for the therapeutic, which gave it a longer patent life and tax incentives to reduce the cost of clinical trials. Drugs given this status are for treating patient populations of 200,000 or under.
Bio... |
| 27.11.2012 | Novo Nordisk boosts app armory with hemophilia gaming, blood disorder tracking apps | “We are about to launch the Novo Rocket Trooper Gaming app. This game takes the patient through a maze of asteroids and has them answer disease state information questions giving them additional turbo boosts and force fields. The objective ... |
| 16.02.2012 | Hemophilia therapeutic from CSL Behring gets orphan drug status | One complication associated with hemophilia is that patients develop inhibitor antibodies against normal factor VIII coagulation proteins because of frequent infusions. In hemophiliacs, the normal antibody is treated as foreign because the ... |
| - | Hemophilia therapeutic from CSL Behring gets orphan drug status | A drug therapy for hemophilia patients developed by CSL Behring has been given orphan drug status by U.S. regulators.
The hemophilia therapeutic from CSL Behring, a plasma protein therapeutics producer in King of Prussia, Pennsylvania, link... |
| - | Therapeutic could improve hemophilia B patients’ quality of life with reduced jabs | A drug developer has initiated enrollment for a phase 3 trial for a hemophilia therapeutic that could reduce the frequency that people with the rare blood disorder need to take medication. The move is part of a larger trend of biotechnology... |
| - | Novo Nordisk boosts app armory with hemophilia gaming, blood disorder tracking apps | Novo Nordisk has launched its ninth app to help hemophiliacs and caregivers track bleeding events and medications. The Danish drug developer has been deepening its blood disorder diagnostic tools aimed at healthcare professionals as well as... |
| - | CSL Behring, uniQure in $2B deal to in-license hemophilia gene therapy | A Dutch biotech company developing a gene therapy for hemophilia has made a deal with the U.S.-based division of an Australian company that will enabled it to be marketed around the world.
Amsterdam-based uniQure said Wednesday that King of... |
| - | Rare disease biotech picks up $8M, drug development partner for DNA-based therapies | Amid somewhat of a renaissance in drug development for orphan diseases, another gene therapy company announced funding today for a potential treatment for a rare neurodegenerative condition called Friedreich’s ataxia (FRDA).
Agilis Biothera... |
